Individual investors among Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) largest shareholders, saw gain in holdings value after stock jumped 3.2% last week

Key Insights

• Shanghai MicroPort Endovascular MedTech's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public
• 50% of the business is held by the top 12 shareholders
• 16% of Shanghai MicroPort Endovascular MedTech is held by Institutions

A look at the shareholders of Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHSE:688016) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are individual investors with 42% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

As a result, individual investors collectively scored the highest last week as the company hit CN¥13b market cap following a 3.2% gain in the stock.

Let's take a closer look to see what the different types of shareholders can tell us about Shanghai MicroPort Endovascular MedTech.

Check out our latest analysis for Shanghai MicroPort Endovascular MedTech

What Does The Institutional Ownership Tell Us About Shanghai MicroPort Endovascular MedTech?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

Shanghai MicroPort Endovascular MedTech already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Shanghai MicroPort Endovascular MedTech's earnings history below. Of course, the future is what really matters.

Hedge funds don't have many shares in Shanghai MicroPort Endovascular MedTech. MicroPort Scientific Corporation is currently the largest shareholder, with 41% of shares outstanding. With 1.6% and 1.4% of the shares outstanding respectively, Hwabao WP Fund Management Co., Ltd and Taikang Asset Management Co., Ltd. are the second and third largest shareholders.

After doing some more digging, we found that the top 12 have the combined ownership of 50% in the company, suggesting that no single shareholder has significant control over the company.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Shanghai MicroPort Endovascular MedTech

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

We note our data does not show any board members holding shares, personally. Given we are not picking up on insider ownership, we may have missing data. Therefore, it would be interesting to assess the CEO compensation and tenure, here.

General Public Ownership

With a 42% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Shanghai MicroPort Endovascular MedTech. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Public Company Ownership

It appears to us that public companies own 41% of Shanghai MicroPort Endovascular MedTech. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Shanghai MicroPort Endovascular MedTech better, we need to consider many other factors. Be aware that Shanghai MicroPort Endovascular MedTech is showing 2 warning signs in our investment analysis , and 1 of those shouldn't be ignored...

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.